October - December 2015, Volume 11, Issue 4

Darwish IE, Ismail CA, Guemei AA, Abdelbary A

Role of Targeting Asymmetric Dimethylarginine in Streptozotocin-Induced Diabetic Nephropathy in Rats: Effects of Taurine and Rosiglitazone

Acta Endo (Buc) 2015, 11 (4): 449-456
doi: 10.4183/aeb.2015.449

Introduction. Insulin resistance or dysfunction of pancreatic beta cells represents one of the important worldwide endocrine disease challenges. In fact, vascular endothelial dysfunction (VED) is involved in the pathogenesis of one of the most significant causes of diabetes-induced morbidity; diabetic nephropathy (DN). Asymmetric dimethyl arginine (ADMA) is one among other incriminating mechanisms of VED. The aim of this study was to assess whether ADMA modulation could be achieved by taurine or rosiglitazone, and whether they could improve tubulo-interstitial ischemia and subsequent renal damage in experimental DN in rats. Material and methods. 40 male Wistar rats were randomly assigned into 4 groups: normal saline-injected control, diabetic control induced by intraperitoneal injection of streptozotocin (STZ) (45 mg/kg), and two diabetic groups daily treated orally with rosiglitazone (3 mg/kg) and taurine (500 mg/kg) respectively, for 12 weeks after STZ injection. Results. Both rosiglitazone and taurine treatments significantly decreased fasting blood glucose, renal functions (serum creatinine, blood urea nitrogen, albuminuria), and renal oxidant potential (Malondialdehyde), as well as, tumor necrosis factor-alpha (TNF-α). They also significantly improved renal antioxidant capacity (reduced glutathione) and histopathological changes. Furthermore, taurine significantly diminished serum ADMA, while rosiglitazone showed no significant effect. Conclusion. The present study suggests that the treatment with rosiglitazone or taurine can reduce the progression of renal damage in streptozotocin-induced diabetic nephropathy in rats by different mechanisms. However, reducing ADMA could be a potential therapeutic target.

Keywords: Diabetic nephropathy, streptozotocin, rosiglitazone, taurine, ADMA

Correspondence: Inas El Sayed Darwish MD, PhD, Faculty of Medicine, Clinical Pharmacology, Al Moassat Medical Campus, Alexandria University, Alexandria, 00203, Egypt, E-mail: inas.darwish@alexmed.edu.eg